Schott inaugurates new melting tank after €25 million investment

Pharmaceutical glassmaker Schott has inaugurated a new melting tank in its Gujarat, India facility with an approximate investment of €25 million.

The new tank will increase the plant’s production capacity by 10,000 tonnes to reach an annual capacity of 40,000 metric tonnes.

Schott has been committed to providing its specialised pharma glass used for storing billions of Covid-19 vaccines.

The melting furnace has been constructed within a span of one year, to enable a 25% increase in the facility’s overall production capacity, to support the pharma industry that is facing a huge demand surge for pharma packaging products.

Schott Glass India’s MD, Pawan Shukla said: “Schott remains committed to ensure that there is adequate supply of its high-quality pharma glass for the Indian pharma industry.

“Moreover, as Schott’s manufacturing hub in Asia, we have taken up the responsibility to cater to our clients in India as well as in neighbouring countries.”

The melting tank is a part of the company’s commitment to invest over €47 million in its Indian facility, and to double its capacity of producing the highly specialised Fiolax tubing material for both domestic and export demands.

The expansion has resulted in additional employment of over 120, taking the overall count to 420 employees.

German Project Engineer and Expert for Melting Technology, Norbert Osterhage, who was overseeing the project, chose to stay in India during the lockdown.

This was to ensure that the melting tank is operational in time, especially now as quality glass vials and syringes have become need of the hour for Covid-19 treatment.

Dr. Patrick Markschläger, Executive Vice President, Schott AG, Business Unit Tubing explained: “Schott is already providing its glass to majority pharma packaging leaders for storing COVID-19 medication, and delivering glass vials to three out of every four COVID-19 vaccine projects undergoing various phases of testing.

“Our Indian facility is an integral part of our pledge to cater to any requirement of the pharma industry in a sustainable manner.”

23.11.2020, Schott AG

News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.